Skip to main content
. Author manuscript; available in PMC: 2023 Sep 5.
Published in final edited form as: J Nat Prod. 2022 Mar 15;85(3):657–665. doi: 10.1021/acs.jnatprod.2c00015

Table 1.

SARS-CoV-2 inhibition in human Calu-3 cells by 13.

Compound EC50 (μM) a CC50 (μM) a
Homofascaplysin A (1) 1.1 ± 0.4 ~5
(+)-Aureol (2) 4.0 ± 1.0 >10
Bromophycolide A (3) 6.9 ± 2.0 >10
Remdesivir 0.3 >5 b
DMSO control 8.3 ± 1.5 >10
a

EC50 and CC50 were determined from dose response in Calu-3 cells. Averages from three independent experiments shown with standard error of the mean.

b

Literature precedent shows that CC50 for remdesivir was >40 μM against Calu-3 cells.43